GlobalData on MSN6mon
Spur Therapeutics to begin Phase III gene therapy trial in Gaucher diseaseSpur Therapeutics has announced that its gene therapy candidate for Gaucher disease will soon be moving to a Phase III trial after positive early data from a Phase I/II trial. Spur, which is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback